- Home
- GPAT vs EBS Comparison
GPAT vs EBS Comparison
Compare GPAT & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GPAT
- EBS
- Stock Information
- Founded
- GPAT 2020
- EBS 1998
- Country
- GPAT United States
- EBS United States
- Employees
- GPAT N/A
- EBS 900
- Industry
- GPAT
- EBS Biotechnology: Pharmaceutical Preparations
- Sector
- GPAT
- EBS Health Care
- Exchange
- GPAT NYSE
- EBS Nasdaq
- Market Cap
- GPAT 379.9M
- EBS 359.3M
- IPO Year
- GPAT 2024
- EBS 2006
- Fundamental
- Price
- GPAT $10.53
- EBS $7.30
- Analyst Decision
- GPAT
- EBS Strong Buy
- Analyst Count
- GPAT 0
- EBS 3
- Target Price
- GPAT N/A
- EBS $14.33
- AVG Volume (30 Days)
- GPAT 51.6K
- EBS 1.4M
- Earning Date
- GPAT 01-01-0001
- EBS 08-05-2025
- Dividend Yield
- GPAT N/A
- EBS N/A
- EPS Growth
- GPAT N/A
- EBS N/A
- EPS
- GPAT 0.36
- EBS N/A
- Revenue
- GPAT N/A
- EBS $965,400,000.00
- Revenue This Year
- GPAT N/A
- EBS N/A
- Revenue Next Year
- GPAT N/A
- EBS $18.88
- P/E Ratio
- GPAT $29.50
- EBS N/A
- Revenue Growth
- GPAT N/A
- EBS N/A
- 52 Week Low
- GPAT $9.99
- EBS $4.02
- 52 Week High
- GPAT $10.64
- EBS $15.10
- Technical
- Relative Strength Index (RSI)
- GPAT N/A
- EBS 62.33
- Support Level
- GPAT N/A
- EBS $6.59
- Resistance Level
- GPAT N/A
- EBS $7.29
- Average True Range (ATR)
- GPAT 0.00
- EBS 0.39
- MACD
- GPAT 0.00
- EBS 0.05
- Stochastic Oscillator
- GPAT 0.00
- EBS 92.89
About GPAT GP-ACT III ACQUISITION CORP
GP-Act III Acquisition Corp is a blank check company.
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.